Kevin C. Conlon
Staff Clinician
Center for Cancer Research
National Cancer Institute
United States of America
Biography
Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.
Research Interest
mmunotherapy, IL-15
Publications
-
Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. Journal of Immunotherapy. 2012 Oct 1;35(8):629-40.
-
Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 2013 Jan 17;121(3):476-84.
-
Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood. 2013 Mar 14;121(11):2029-37.